Sarilumab治疗重症或危重症COVID-19住院患者的随机双盲安慰剂对照3期试验
这项在11国45家医院开展的60天随机双盲安慰剂对照3期试验,纳入420例需氧疗或重症监护的COVID-19住院成人,比较静脉Sarilumab 400 mg、200 mg与安慰剂的疗效。主要终点第29天临床改善时间及生存比例均无显著差异,未发现意外安全信号,提示Sarilumab对这类患者无效。
要点
- Sarilumab 200 mg和400 mg组临床改善时间与安慰剂无显著差异。
- 第29天生存比例三组间无显著差异,危重症亚组差异亦无统计学意义。
- 治疗中出现的不良事件发生率三组相近,未发现意外安全信号。
核心结论
- 本试验未显示Sarilumab对需补充氧气的COVID-19住院患者有效。
- 建议在危重症COVID-19患者中开展以生存为主要终点的充分把握度靶向免疫调节试验。
研究设计与样本
- 60天随机双盲安慰剂对照跨国3期试验,在阿根廷、巴西、加拿大、智利、法国、德国、以色列、意大利、日本、俄罗斯和西班牙的45家医院开展。
- 纳入≥18岁、实验室确诊SARS-CoV-2感染且患肺炎、需补充氧气或重症监护的住院成人。
- 420例患者按2:2:1随机分配接受静脉Sarilumab 400 mg、200 mg或安慰剂,416例实际接受治疗。
主要发现
- 治疗中出现的不良事件发生率:安慰剂65%(55/84),Sarilumab 200 mg 65%(103/159),400 mg 70%(121/173);导致死亡的不良事件分别为11%(9/84)、11%(17/159)、10%(18/173)。
临床怎么用
- 不推荐对需补充氧气的COVID-19住院患者常规使用Sarilumab。
- 危重症COVID-19的免疫调节治疗仍需以生存为主要终点的充分把握度试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. METHODS: We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 hospitals in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. We included adults (≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomly assigned (2:2:1 with permuted blocks of five) to receive intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. Patients, care providers, outcome assessors, and investigators remained masked to assigned intervention throughout the course of the study. The primary endpoint was time to clinical improvement of two or more points (seven point scale ranging from 1 [death] to 7 [discharged from hospital]) in the modified intention-to-treat population. The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This study is registered with ClinicalTrials.gov, NCT04327388; EudraCT, 2020-001162-12; and WHO, U1111-1249-6021. FINDINGS: Between March 28 and July 3, 2020, of 431 patients who were screened, 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), sarilumab 200 mg (n=159 [38%]), or sarilumab 400 mg (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12·0 days [95% CI 9·0 to 15·0]) and sarilumab 200 mg (10·0 days [9·0 to 12·0]; hazard ratio [HR] 1·03 [95% CI 0·75 to 1·40]; log-rank p=0·96) or sarilumab 400 mg (10·0 days [9·0 to 13·0]; HR 1·14 [95% CI 0·84 to 1·54]; log-rank p=0·34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference -1·7 [-9·3 to 5·8]; p=0·63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0·2 [-6·9 to 7·4]; p=0·85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8·9% [95% CI -7·7 to 25·5]; p=0·25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group. INTERPRETATION: This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19. FUNDING: Sanofi and Regeneron Pharmaceuticals.
引用
- Lescure FX, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021. PMID: 33676590. doi:10.1016/S2213-2600(21)00099-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。